Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Antares Pharma, Inc. (NASDAQ: ATRS).

Full DD Report for ATRS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ATRS)

Institutional Top Ideas Series: Opaleye Management
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund we´ve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds ...
Source: SeekingAlpha
Date: May, 17 2018 01:52
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
Antares Pharma's (ATRS) CEO Robert Apple on Q1 2018 Results - Earnings Call Transcript
Antares Pharma, Inc. (NASDAQ:ATRS) Q1 2018 Earnings Conference Call May 8, 2018 8:30 AM ET Executives Jack Howarth - VP, Corporate Affairs Robert Apple - President and Chief Executive Officer Fred Powell - Executive Vice President and Chief Financial Officer Analysts Ore...
Source: SeekingAlpha
Date: May, 08 2018 14:08
Antares Pharma Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Antares Pharma Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 08 2018 08:38
Antares Pharma misses by $0.01, misses on revenue
Antares Pharma (NASDAQ: ATRS ): Q1 EPS of -$0.04 misses by $0.01 . More news on: Antares Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 07:08
Antares Pharma Reports First Quarter 2018 Operating and Financial Results
EWING, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the Company) today reported operating and financial results for the first quarter ended March 31, 2018.  The Company reported revenue of $12.7 million and a net loss per share of $0.04 for the quarter end...
Source: GlobeNewswire
Date: May, 08 2018 07:00
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space
Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size...
Source: SeekingAlpha
Date: May, 07 2018 15:40
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 43rd Annual Health Care Conference
EWING, N.J., May 02, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 10:00 am Eastern Time...
Source: GlobeNewswire
Date: May, 02 2018 07:00
Antares Pharma to Report First Quarter 2018 Financial and Operating Results
EWING, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its first quarter 2018 financial results and recent operating progress before the market opens on Tuesday, May 8, 2018.  Management will host a webcast and conference call a...
Source: GlobeNewswire
Date: May, 01 2018 07:00
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond
Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size...
Source: SeekingAlpha
Date: May, 01 2018 02:41

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-203.453.453.4793.371,664,254
2018-08-173.483.413.503.272,819,876
2018-08-163.213.303.543.154,130,611
2018-08-153.263.183.283.15907,907
2018-08-143.263.273.323.151,733,665

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-20295,446599,14349.3114Short
2018-08-17488,1451,075,14745.4026Short
2018-08-16827,1341,619,27951.0804Short
2018-08-15192,615420,04645.8557Short
2018-08-14258,907685,67537.7594Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATRS.


About Antares Pharma, Inc. (NASDAQ: ATRS)

Logo for Antares Pharma, Inc. (NASDAQ: ATRS)

Not available

 

Contact Information

 

 

Current Management

  • Paul K. Wotton / President, CEO
  • Robert Apple / CFO

Current Share Structure

  • Market Cap: $391,972,465 - 05/14/2018
  • Issue and Outstanding: 156,788,986 - 03/01/2018

 


Recent Filings from (NASDAQ: ATRS)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 13 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: ATRS)

Daily Technical Chart for (NASDAQ: ATRS)


Stay tuned for daily updates and more on (NASDAQ: ATRS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ATRS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATRS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ATRS and does not buy, sell, or trade any shares of ATRS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/